This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.drvinayprasad.com/subscribe
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
SPEAKER_00How do you divide your time? I mean, I'll probably ask you this again in a few minutes, but how do you divide your time between writing? I see you write a lot. Do you actively treat patients? How does that work?
SPEAKER_01I'm a professor, practicing clinician, hematologist, oncologist. I've worked here at University of San Francisco since, what, 2020? And my schedule has always been different over the years going from You know, a couple days a week in the clinic to a few months a year on service, different hospitals. I've rounded at the VA, at the county hospital, mostly with the fellows. I love to be on with, you know, the residents and fellows because you can kind of teach them. And before that, I was in Oregon for five years and I did bone marrow transplant, leukemia.
SPEAKER_01But I mentioned all of Hemonc and I pretty much do all of Hemonc. And then I guess I also do a lot of second opinions that people ask me through the grapevine. And then, you know, I'm on YouTube. I'm on Substack. I'm reading your stuff on Substack. And I'm on Sensible Medicine, Twitter, less so these days, you know, do that kind of stuff. And then a little bit of people ask me questions here or there.
SPEAKER_00How do you balance, how do you balance it all? Are you, I mean, do you have like a fairly small patient? I just, it seems, you know, knowing, I mean, my dad died of, you know, a Yeah, I mean...
SPEAKER_01You know, I told somebody once a few years ago that I think it had been like 10 years in my life that I hadn't gone a day without at least one or two calls about patients or from patients, you know, for 10 years, every holiday, every vacation, you know, like for 10 years when I went to the FDA, of course, I had to, you know, close up my clinic for a year. Um, so that was unfortunate. That's a huge drag, uh, about that job, to be honest. Um, I always like to say when healthcare policy, they can undo everything, but no one can undo the care you provide for a patient.
SPEAKER_01That's something that's forever. So I feel like clinical medicine is why most of us get into this business. It's still the most satisfying. But your question about volume of patients. I don't pretend to take care of as many people as a private practice community oncologist would, which may be many, many times more. And there are people who do 60, 65 hours, 80 hours, 85 hours, 90 hours a week of clinical medicine. It's impressive and it's very demanding. But about your dad, I'm sorry to hear that. I'm sorry to hear that.
SPEAKER_00But you are a true practicing clinician. You're not Tony Fauci. You continue to see patients.
SPEAKER_01Yeah, I'm not a career bureaucrat. You know, Fauci and Hosni Mubarak, the only people who ran a place for 40 years, yeah.
SPEAKER_00Yes, and it worked about as well in both.
SPEAKER_01But I do also want to point out that, you know, in these pissing contests of, you know, Jay Bhattacharya, he didn't do residency and Fauci did do residency. I just feel like it's not a productive thing. Right, right.
SPEAKER_00Big questions. I mean, this is sort of a big question, but let me ask you, since we are, you know, I mentioned my dad, we're talking about leukemia. That's what you specialize in or hemo generally. Is this a place where, you know, I'm pretty cynical about medical advances and the cost, but is this a place where we've actually made progress in the last 10 to 20 years? I mean, is this a place where you can offer patients more hope Legitimate hope than you could have at the beginning of your career.
SPEAKER_01With MDSAML specifically? Yeah. I guess I would say, boy, it's kind of a tough question. I mean, let me say what the oncologist would say. The oncologist would say, we've had a number of revolutionary new drugs in this space. We've had venetoclax, the BCL-2 inhibitor, in combination with azacitidine. We have an improvement in survival from something like 8 months to 14 months or 10 to 14 months in VR. We've got second generation drugs, giltritinib, menin inhibitors. We've got all these kind of salvage drugs.
SPEAKER_01And we've got bone marrow transplant. We're doing reduced intensity transplant. We're curing people. I think that's what a lot of oncologists would say, a story of incremental progress. I don't disagree with that. I mean, I think there have been some modest steps there, but I think if we step back and look at the big picture, it's still a very tough diagnosis. I mean, MDS turning to AML is a very tough diagnosis. The only path to cure is transplant. It's few and far That's interesting because my dad was diagnosed, I think, in
SPEAKER_00Uh, I want to say August, 2017. And that was off. He just, he just took a blood test. It was not, uh, you know, he didn't have clinical symptoms at that point. He didn't have, you know, shortness of breath or anything. Uh, and then when, when did it turn into, uh, he was diagnosed with MDS, I should say.
SPEAKER_01Yes. Yes. That was MDS.
SPEAKER_00And he was dead in May of 2020. So less than three years. I'm sorry.
SPEAKER_01I'm sorry to hear that.
SPEAKER_00But, but that sounds like That's been the case for a really long time and hasn't changed that much.
SPEAKER_01Yeah. And I think from 2020 till now, you know, maybe there are a few different drugs we'd offer. There've been a bunch of approvals, but that story hasn't changed all that much, you know, for the last 50, 60 years. You know, it's a tough story. Yeah.
SPEAKER_00So one thing that has changed, and now let's pull back to the other side of this, is the cost. The cost of treating somebody like my dad, I imagine, maybe 30 years ago was relatively modest and now might be a million dollars for those three years.
SPEAKER_01Or more, I would say, you know, look at RevMed, Revolution Medicine. They have a RAS inhibitor. It's priced at $477,000 per year of treatment. I mean, Alex, just to give you some perspective, in the late 1990s... We had Paclitaxel, which was a BMS drug, and it came to market. And people said, wow, this is the first cancer drug that's going to earn $1 billion annually. It's the first blockbuster cancer drug. Before Paclitaxel, people said, if you want a blockbuster drug, it's got to be That seems like a steal.
SPEAKER_01You know, now $30,000 a month. And what you've seen is relentless, relentless increases in price. The older drugs that were approved five years ago have year over year price increases of like 9% to 10% on average. The new drugs are just launched at whatever the number is that will get you on 60 minutes minus $100. That's what they're launching it. It's just one notch below shame. Yeah. Right.
SPEAKER_00I mean, I don't know. Is it one that's below shame or is it just shame that we've sort of lost any ability to realize?
SPEAKER_01I mean, I think Scarelli was the one that flew too high. You know, he took Daraprim, Turing Pharmaceutical. He took an old drug that had been around a long time. He cranked up the price and he got dragged in front of Congress, which is what people don't want. And then he made the biggest mistake anyone made, which was he's rude in front of Congress, which led them to come up with a reason to put him in prison. Yes.
SPEAKER_00Yes.
SPEAKER_01Fauci did the same thing to Rand Paul, and that's why he's getting a taste of his own medicine too.
SPEAKER_00Well, you and I wouldn't know anything about being unnecessarily weak. We're just extremely polite, quiet people.
SPEAKER_01Well, certainly if we were dragged in front of Congress, I'd put on my polite hat.
SPEAKER_00Yes, one of the few times I've testified, and it's generally been friendly. No, I find it, I do find it intimidating. You have to have pretty big cojones to go up there and testify that way. I agree. But so, is there any, and again, we're talking about pricing again, at this point, the pricing of new drugs for anybody who just joined the call, and new cancer drugs in particular. Is there any limit? Is there any limit? Is there any payer pushback?
SPEAKER_00Is there any federal pushback? Is there anything that is going to stop this? Or are we just going to pay more and
SPEAKER_01more and more? Yes, we're just going to pay more and more. There's no pay or pushback. I think this is a big misconception people have, which is that, wow, UnitedHealthcare makes more money if they said no to all these drugs. Let me give you one fact. The Affordable Care Act caps the medical loss ratio at a certain number, which means out of every $100 you spend, 80 cents or 85 cents has to be spent on health care. So imagine, Alex, we go out to eat dinner and it's going to go get some pizza. And I tell you, Alex, that you can eat 15% of the pizza.
SPEAKER_01What size should we order? You can only eat 15% of the pizza. What size should I get? You're going to say extra, extra large. So the payers want to grow healthcare. What they care about is... They don't want an unpredictable year-to-year growth. They want to buffer the year-to-year growth. But over the long haul, UnitedHealthcare would happily have us pay $10 trillion as a society on healthcare. What are we, $2 trillion, $3 trillion now, $4 trillion?
SPEAKER_00I believe we're over $5 trillion.
SPEAKER_01$5 trillion? Yes. Yeah, I think that's probably pretty close to right, yeah.
SPEAKER_00I mean, yes, and of course they've seen that the other way they can make money is by sort of accumulating, you know, physician practices or, you know, ERs or, you know, urgent care clinics. They can buy up, you know, nodules within the system.
SPEAKER_01Yes, I certainly think that the private equity people have moved in. They're buying up everything. We have an AI arms race. AI is like the doctor's note is using AI to bill more. The insurance company is using AI to deny more. But again, that's just a year to your buffer. Two years from now, they'll just change our premiums and jack them up and then they'll be happy as a clam. Yeah. If you want to say of the $5 trillion, how much of it actually goes to healthcare that makes our lives better, that's perhaps a tiny fraction. There's all sorts of parasites leeching off this animal.
SPEAKER_01Right.
SPEAKER_00So speaking of parasites, you were at the FDA. Is that me?
SPEAKER_01Oh, right. Oh, well, the system. Yeah, I saw the system. So tell me about
SPEAKER_00Sort of birth to death, and it wasn't that long, but, you know, how you got in, what you hoped you would accomplish, what you ran into on the inside, and what you, you know, how you wound up falling on your sword. And then we can, you know, that's a big, sort of a big, give us the 50,000 foot and then we can drill down a little bit.
SPEAKER_01Well, as a child, Alex, I dreamed of being a career bureaucrat. You know what I mean? No, I'm just kidding. Yeah. No, I mean, I was very happy before and after, and I was very happy doing what I always wanted to do, which is, you know, see some patients, teach some classes, write some papers, write some blogs, make some videos and, and, you know, and do some exercise. You know, you know, you know, I'm a simple creature, but, you know, I enjoyed my time before I went into the FDA and Largely because I felt like there was a great moment and great opportunity
SPEAKER_01for some real reform. I had been a longtime critic of the agency. And, you know, if you've been a critic of anything and somebody gives you a chance to go in and fix what you've criticized and you say no, well, shame on you.
SPEAKER_00And who recruited you? Was it Marty? Was Jay involved? Was RFK involved? Who recruited you? You were not at a position, I assume, where Trump directly was involved.
SPEAKER_01But no.
SPEAKER_00But who recruited you?
SPEAKER_01That's that's fair. Well, so Jay and I have been friends for many years through the pandemic, because obviously Jay, me, John Yonides, you know, Chirag Patel, Iran Ben David, the people, Scott Atlas, like we all live in the same area and we're kind of like minded. So we know each other. Marty, I met through Zubin Damani, a ZDogg MD on YouTube. Longtime friends with Marty and Marty flew into town maybe in 2022 and 23. Every time we met, you can watch it. There's a video on YouTube. We hit it off like on the show and at dinner after and things like that.
SPEAKER_01And so Marty was in touch with me when Trump One, Marty was like, you know, clear your calendar. You know, he basically was like, you know, might be nice for you to help out. And so Marty was the one who approached me and said, you know, would love to have you at FDA. Bobby, I had been in touch with Bobby over the years and Bobby's team and Kelly Means and such. And, you know, there's a great deal of overlap. There's also some, you know, disagreements that I have with them. Yeah. Marty and me are probably closer, and Jay and I are probably closer. You and I are probably closer, you know, in terms of, like, overall views on healthcare issues.
SPEAKER_00So, yeah, I mean, this is an issue that I think doesn't get explored or understood that much, or, you know, to the extent that, like, the legacy media talks about it, they don't really want to talk about it, which is that you, I'd say... You and me, we're pretty evidence, like very evidence heavy, right? And so Maha, I would say, is not always that way. So were you able, and I don't know how much you talked to RFK directly,
SPEAKER_00were you able to get, you know, your feelings about, you know, the need for clinical trials or the need for, and I don't want to put words in your mouth. Maybe you think, you know, that in certain cancer cases, people should not, you know, we should be progressing pretty quickly. But let me let me frame it a little differently. Is there a tension between your view of the strictness and strength of evidence that is needed to approve new medicines and,
SPEAKER_00you know, and let's say non-drug therapies and what, you know, the Maha sort of feeling of right to try of let's, you know, Let's go with some stuff that we're not sure how well it works, but people need to be able to make these decisions for themselves. Is there attention there? And if so, how do you resolve it?
SPEAKER_01Yeah. Okay. Well, I think it's a good question. And I'm going to answer your question, but maybe let's just step back for a minute and be like, you know, where am I? And I do think I'm close to you in the sense that we're kind of evidence-based, we're stricter people when it comes to evidence. What do we agree with Maha? Where are the places we disagree with? You know, COVID-19 vaccines being overprescribed to young people, boosters being probably unnecessary, COVID-19 vaccines to pregnant women. I think you and I and Maha are all kind of aligned that, boy, what have we done here? Do we have the appropriate evidence?
SPEAKER_01Is this observational data good enough? What are some problems there? Pax Levit, I think we're all aligned. Like, what is this Pax Levit? Does it have evidence of people who've been, had COVID or been vaccinated? Childhood immunizations, you know, I think I tend to be a believer in the majority of them, but there are still some places where I think reasonable people can ask good questions like, does a mother who's hep B negative, not a drivey drug user, not a promiscuous sex person, having a baby, does she need that hep B shot in the baby that minute that it's born?
SPEAKER_01Or can we wait a little bit? These are places where I think Maha has some truth. The food we eat, the poisonous food we eat with chemicals, like I'm on board with the Maha Agenda, the dyes and pesticides in our environment, I'm on board. I think precautionary principle applies a lot there. You know, places where I think there's a little friction. Does Tylenol while being pregnant contribute to autism? I'm rather agnostic on that question. I think that I do advise a pregnant woman, don't take anything unless you absolutely need to. I think that's good, prudent advice through the centuries.
SPEAKER_01But this particular study... And when it comes to the vaccine agenda... Right now, I think Bobby has got a lot of studies going, but they're largely the observational type, the kind that I'm going to find dissatisfying, probably you too. I would have liked to see more randomized studies like we outlined in our COVID policy memo and some other leaked memos. But when it comes to the trying, let's talk about the trying the drugs.
SPEAKER_00Yeah, I think that's a real sort of hot button issue for people who say, you know, I'm dying of cancer. I should be able to try what I like.
SPEAKER_01Yeah, so I feel like there are two things you can say. One is that it's your body, you're dying. Like, of course, you should be able to try things that I might not try for myself. And the second thing I'd say is a drowning man will reach for a blade of a sword. What I mean is that somebody who's sick and desperate and dying will often grasp for something, even if it can hurt them. And I think we think that the worst thing that can happen to you is you die anyway. I hate to say it, that's not the worst thing that can happen to you.
SPEAKER_01The worst thing that can happen to you is you're going to die anyway in three months or six months. But along the way, you have the most gut-wrenching misery of your life. You have your nerves demyelinate. You have your... Skin slough off. You have pouring blood from your face. That's a successful therapy, by the way. The Daron Rex's, the Ben Sass face, that's a successful drug. It improved OS, but it still has that side effect. There are drugs that have side effects the likes of which you can scarcely imagine, like torture. So anyway, I come into this and I say, why do we have the FDA?
SPEAKER_01I mean, if we were to say for any reason, it's that we want to shield a sick and dying person from reaching for the sword when you're drowning from reaching for the blade. Right.
SPEAKER_00But that's an interesting point and one that I think doesn't get made enough that, yes, somebody who has a fatal disease, you think that there's no downside, but there is actually downside, whether that's dying even more quickly or these terrible side effects that you mentioned.
SPEAKER_01Like Huntington's disease is a terrible way to die. But what might be worse along the way is if someone drilled holes in your skulls or injected your striatum or something in your brain with something that doesn't work, that hastens death, that causes all this pain. And the other thing is like one in a hundred, one in a thousand, one in 10,000, you start monkeying with someone You're going to have a bad side effect. You know, one in 10,000 people who get a colonoscopy may get a perforation. One in 100 people get a lung biopsy may lose a lung. One in 10,000 people who get a lung biopsy may die, you know, from a series of medical diseases.
SPEAKER_01I think we have to be cautious there too. Back to Maha, I think when it comes to rare disease, we were doing things on both sides of the ledger that the media didn't cover. I was made a pathway, the plausible mechanism pathway, where the The bar for really N of 1 bespoke gene editing is going to be very permissive and low because you can't really generate evidence in that case. At the same time, there are places we can generate evidence. And honestly, Maha, to me, is not in conflict with that as much as it is the SSL.
SPEAKER_01Right.
SPEAKER_00Right. The Susie Wiles, the Scott Gottlieb, all the people who who.
SPEAKER_01Well, I like Susie. I like Bobby Scott. No comment.
SPEAKER_00Do you like Susie? That's interesting. So you don't think she's a sort of a bad actor in all of this?
SPEAKER_01I feel like it's hard to, well, first of all, I think she is, whatever anyone wants to say, doesn't she run that place very well? I mean, to run a Trump White House the way she's run it, keeping herself in position of control and keeping it under wraps and no leaks, I think, like just as a tactician, she's skilled. In terms of what's her philosophical belief, you know, in some ways I do kind of, you know, she hasn't been following this field for 30, 40 years and doesn't always have all the arguments in her ear.
SPEAKER_01She may be hearing disproportionately from lobbyists, you know, and not from those of us who are kind of more in this reform healthcare policy movement that has some overlap with the Republican Party. She's not hearing from us as much. So, you know, I don't view her as a bad actor, personally.
SPEAKER_00So, so in the end of November last year, I mean, you'd already had one sort of, uh, one blow up where you basically, you know, been shown the door and returned, uh, Lazarus like, um, but, uh, But at the end of November, you put out a statement saying the mRNA shots killed children. You know, we reviewed the evidence. We found this. And I want a very different statement.
SPEAKER_00Sort of attitude towards these or towards the evidence we're going to use to support the use of these in, you know, in children and in people under 65 going forward. And by the way, if you don't agree with me or if you plan to leak this. That's correct. Correct. Correct distinction. Maybe it's time for you to find a new job. Yeah, if you plan to leak it. A real shot across the bow in many ways. What?
SPEAKER_01Yeah.
SPEAKER_00What did you? What? What were you? What were you doing? And were you surprised that the blowback was so fierce?
SPEAKER_01OK, what was I doing? I mean, well, first of all, if you work at the agency and you're planning on leaking things because you disagree with the people who came into power, then you should resign. You should still resign because we don't need a fourth branch of government that's unelected, that's not accountable to the body politic, that's discriminated. Deciding the preferences of this nation. We don't need you. And I know you think you're doing good, but that would be one thing if you had a spotless track record. But anyone who's read Berenson or Prasad for the last five years knows the COVID-19 pandemic and the regulation around that is a series of screw ups.
SPEAKER_01It's just misstep after misstep. So they've gotten so many things wrong. OK, let me give you a little bit of a background for this memo. You may remember that when we came in, Marty and Tracy were both very interested in a very specific claim, which is, did the COVID-19 mRNA vaccines kill somebody? Did it kill zero people or more than zero? It's a very simple binary claim. And I just want to start with, like, what did we know? We knew Janssen and AstraZeneca. Did it kill zero or more than zero, Alex? More than zero.
SPEAKER_01More than zero because it has vaccine-induced thrombocytopenia and thrombocytopenia. It definitely killed people. It killed an 18-year-old girl in Europe, for instance. And the reason I want to draw attention to this is...
SPEAKER_00By the way, I would argue, and I don't want to step on the conclusion that you reached, that this question had been answered. Oh, it's been...
SPEAKER_01See, well... Alex, you're speaking to a different audience. You and I know the question has been answered. The answer is yes. But they don't know that. The people who work there don't know that the answer is yes. NBC doesn't know the answer is yes. New York Times doesn't know the answer is yes. Washington Post doesn't know. Harvard doesn't know. Harvard may not even know. I mean, that's how sad the state is. Harvard may not know. There are many professors who act like the answer is zero. Okay, so let's go back to the Janssen story. The Janssen story, AstraZeneca story, the side effect is such a unique side effect. In Europe, for instance, there's an 18-year-old girl who's died.
SPEAKER_01So this is an 18-year-old girl who's totally healthy, gets the shot, has a blood clot, cerebral venous thrombosis, herniates her brain, she's dead.
SPEAKER_00By the way, you're talking about a horrible way to die.
SPEAKER_01Horrible way to die. And also, this was a healthy 18-year-old. Did she even have to worry about COVID-19? No. She could have just lived her whole life, never thought about COVID-19. She didn't even need to know the word COVID-19. She would have lived a happy life. And her life is ruined because of this hysteria around her age group and giving this shot. Okay. In the United States, we knew that the mRNA shots had myocarditis. We knew that from the Israelis in February of 2020. We know that myocarditis is It can be mild. It can be asymptomatic troponin elevation. It can be mild and you feel some dyspnea,
SPEAKER_01chest pain, shortness of breath, and you get tested and you find you have it, you know, sort of a mildly symptomatic myocarditis. It can be a little bit more severe. It can actually end up, you can go to the hospital, require some blood pressure support, maybe go to the ICU. It can be even more severe. You require a left ventricular assist device, maybe even a heart transplant, and it can be so severe you die. And, you know, I always like to say, Alex, it's like if if a million people trip on one stair, most of us will walk it off. Some of us will sprain an ankle. A few of us will slip and gash our head. But one person will die.
SPEAKER_01OK, right. So it's so it's not hard to believe that if you have a
SPEAKER_00vaccine with a known side effect of one in three thousand, that somebody died of it.
SPEAKER_01But yet when I entered the FDA, Marty and Tracy were saying that the answer is greater than zero. But a lot of the staff and a lot of the New York and a lot of the outlets were saying the answer is zero. And Alex, what troubles me is they say the claim that the COVID-19 mRNA shot killed greater than one person or greater than zero people, that's the same level of misinformation as like Reiki crystals will heal your cancer. Like they conflate the two things. One is like clearly true and one is clearly misinformation. Okay. So we come in there and Tracy goes through and she sort of analyzes the deaths and
SPEAKER_01And Tracy comes to the conclusion that, you know.
SPEAKER_00And these are based, is this based on VAERS reporting? Is this based on, you know, the FDA actually approaching, you know, coroner's offices directly? How, where is the information coming from?
SPEAKER_01VAERS. And let's just help the audience along this way. Of all the people who get the COVID-19 shot in America, many of which young people under the coercion of their schools and hospitals, et cetera, in their workplace, many of them probably had myocarditis. Many of them didn't seek care. Some of them sought care. Some of them got care. Some of them died. How many of those people actually filled out a VAERS report, a Vaccine Adverse Events Surveillance System report to FDA? We have good data at FDA that the majority of people who start that report
SPEAKER_01What we don't know is of all the people who see a case in their practice, how many even never fill out the report? And you can imagine, I believe the vast majority would never fill out a report because they're in a media environment that says you're crazy for even thinking it's linked, right? Well, and,
SPEAKER_00you know, the Biden administration stuck like six different warnings on the page saying it's a federal crime if you lie. Yeah. And I was getting contacted by people in 2021 and 2022 saying, I filled this out and it was, you know, this was a death case and no one ever even called me that. And so clearly there was a, let's say, reluctance to either, I don't want to say allow, but to make the report filing process easy or to follow up on the information.
SPEAKER_00Absolutely true.
SPEAKER_01And also absolutely true that the Biden administration, which forced you to get the shot, was in a very conflicted position about reporting the safety consequences of them having forced you to get it. They're the most conflicted group out there. They had a series of, in my opinion, You know, poor quality advisors, and I suspect you think the same, who advise them to mandate it in ultra low risk populations and mandate boosters and deny natural immunity, et cetera, et cetera. Just really the lowest of the low quality health care advisors. And they didn't act upon this.
SPEAKER_01Okay, so we get these VAERS reports. There's a contractor whose job is in reports where it's plausible that it's plausibly related to the vaccine to go pull the autopsies if they exist. That contractor, I'll be honest with you, is derelict on duty. There's many reports, autopsies we don't have. And I tried to put a lot of effort into getting that data that was an uphill battle. I'll tell you that. But even with that, those limitations...
SPEAKER_01There are still some reports that are quite concerning. A young person who gets a COVID-19 vaccine and then two days later is found dead with lymphocytes infiltrating the myocardium and all the other causes of myocarditis are kind of excluded. There are still these reports. And I see people in the media say, boy, they say, quote, unquote, no cases were definitively linked, quote, unquote. Boy, that's a really clever downplaying of the way in which we have attribution at an individual case level. So, I mean, when it comes to a randomized study, attribution is very clear.
SPEAKER_01You subtract intervention versus control arm. With this side effect, of course, there is no good randomized data in this age group with long enough follow-up, so we can't do that subtraction. So the way we do attribution is a qualitative attribution on a scale that goes from unlikely to be linked to possible, probably, likely, and certain. To say something is certain or definitively linked requires a standard of evidence that is untenable, that was never going to be shown here. They say that in cases of granuloma on the skin after MMR shot,
SPEAKER_01where you biopsy the granuloma and you find vaccine strain rubella in the granuloma. Then they'll say, okay, certain. Okay, okay, certain. You die of a chikungunya vaccine, a live vaccine, and they sequence the CSF and they find the vaccine strain in it. Okay, certain. But they won't say it here and they'll never say it. And I don't blame them for not saying that's just the rules of the game. You won't get a certain. But you do have likelies. You do have possibles. You do have probabilities. And when I tasked them with going through these reports, they generated a report that said,
SPEAKER_01yes, you have all those types of categories which are considered attributable. Ergo, it is attributable. And they even said, this is the staff people, not Tracy, that it should be on the label. And I think to date, it's still not on the label. Right.
SPEAKER_00Right. So, okay, so you get, so Tracy writes the report.
SPEAKER_01No, no, no. The report is written by, Tracy did her own analysis and she gave a presentation. They were skeptical of that. They leaked their skepticism to certain news outlets. And then I said, okay, you're skeptical of Tracy. I don't blame you. I mean, I agree with Tracy more than you, but I hear you. You make your own report. And then they came back and they kind of agreed with Tracy's fundamental conclusion on the binary question.
SPEAKER_00Interesting. Yeah. And so you, that's when you wrote that memo.
SPEAKER_01Yeah. And then here's what they had been, here's what people had been telling me and still tell me, which is that we reviewed all these cases in real time to which there's only one simple answer. Then why the hell didn't you say it can cause death? If you did do what you said you did, why the hell didn't you come to this conclusion sooner? You only came to this conclusion after I made you do it again. So obviously you didn't do what you said you did or you did it poorly. One of those two has to be the case, right? You see my point.
SPEAKER_00So- At this point, what is your relationship with the people who are reporting to you and the people reporting to them inside this agency? Are they... Is your, you know, is your feeling at this time, like, these people just want me to be gone. Like, they expect to win. Like, I'm not changing any hearts and minds here. Tell me, because this is something I don't think we hear enough about is, like, we, you know, the deep state, we hear the bureaucracy.
SPEAKER_00Like, what is it like to deal with these folks who essentially have, you know, they have permanent tenure and they can reasonably expect that you're not going to be there that long. Is it just we're going to drag our heels until you're gone? Can you make them work? How does it go on a day-to-day basis?
SPEAKER_01So I think there's a big misconception, which is driven by the media, which is that there's this tension between me and the staff. The staff are like anybody in America. There's a spectrum of views. There are people there who probably love me and still love me. They miss me. There are some, you know, I hate not to toot my own horn, but everybody. Everyone will have some fans. OK, there are also people there who think, you know, I brought a bit of a different perspective. I was a professor, an evidence based medicine purist. I empowered them to pursue the evidence based medicine in certain cases where previously that was sort of discouraged.
SPEAKER_01There are probably people there who may kind of view me more neutrally. They'll say, Prasad, you know, I don't agree with everything he says, but, you know, I respect him. I think he's a smart guy. Like when he comes and makes an argument, he's certainly not making things up. He's very data driven, you know, and then the people there who disagree with me and then there are people there who extremely disagree with me and they'll leak it to the media. And we only hear from this tiny fraction. I have honestly, Alex, I have no sense of the distribution. We've never surveyed the people there. So, okay. But in a normal business environment,
SPEAKER_01if you come in and there's a tiny fraction of people who loathe you and are subverting you, you'd be able to fire them all that single day. In government, to be honest, I think you can do it. If you really came into a presidency and the president said, listen, fire whoever you need to fire in your path, you can do whatever you want to do in government with the sanctioning of the president. But the president doesn't always get to hear from everyone who works for the president. And the president is All presidents, I think, are very fearful of the media narrative on their presidency. And so the tension is that the squeaky wheels get the media to sort
SPEAKER_01of carry their water for them. What's it like to work in this environment, Alex? I would say that, you know, you have to do it if you really believe what you're doing is in the best interest of the public, which I agree. I've always believed, you know, I don't have another motive other than wanting to do what I think is right, which I think is also what governs your writing because there are many, there are a few spaces where you and I could have gone along with our tribe, but we go against the current, you know, you and I both do on the same issues, ivermectin and fibendazole, et cetera. We go against our tribe because we are evidence-based people.
SPEAKER_01Yeah. And so I guess I say, so I'm trying to do it for, I think, the public good. It is obviously frustrating anytime you've got people who are kind of working against what you think. And it's really frustrating when I say, and every time this actually occurred where somebody disagreed with me and we had a back and forth about it and really delved into the literature, usually their mind was moved or they found something wrong in their thinking. Uh, I don't want to get into too many specifics, but there were times where they would,
SPEAKER_01I asked people who disagreed with me, bring me the paper that supports your view. And then I do a little journal club on that paper. What are all the things wrong with that paper? Selection bias and, you know, control arm. And one had a mathematical error, you know, for Christ's sakes, you know? So, so, um, You know what it's like, Alex? It's a lot like teaching a class on a tough and controversial issue. In my career teaching, I've been lucky to have won a bunch of teaching awards, but that's not because I think I'm a great teacher. I think it's just because I'm a passionate speaker and students Are starving for a passionate speaker.
SPEAKER_01That's all they want. Even if they hate your guts, they're glad that you said it with some conviction. But there's always some student in my class who would disagree with me. And that's really fun, I think, for the other classmates to try to narrow down where it is we disagree at and then try to see if we can reach a shared understanding.
SPEAKER_00And on some instances... Yeah,
SPEAKER_01go ahead.
SPEAKER_00So you broadly felt that you're... You had a better relationship inside the agency than people like me might have realized. The knives were not out constantly to get you.
SPEAKER_01Well, two things can be true. The median person was probably on my side, but the extreme tail was very powerful. It's just like social media, Alex, which is that it doesn't matter what the average person in the world thinks. It's what the most extreme person with the knife will think. The heckler's veto is powerful.
SPEAKER_00But in this case, the hecklers were being amplified by the New York Times and the Washington Post and CNN.
SPEAKER_01No, no, let me clarify. Points that, yes. No, no, no. There are two groups of amplifiers. On the issues of vaccines, Washington Post, New York Times, they hate Bobby Kennedy. They need Bobby Kennedy gone and they'll do anything to get Bobby Kennedy. So if it has to do, if you can tie a rope to Bobby Kennedy and the issue, it's going to be in those outlets. Bobby Kennedy said fluoride and fluoride and this tooth fell out and this one kid's boy, oh my God, Bobby Kennedy. Bobby Kennedy went back in time and he told the Amish not to like MMO. You know, that's the New York Times. But the stat, the biospace,
SPEAKER_01I don't even know the names of all these kind of the trade publication They have a different audience. Their audience is investors, and investors want return on investment from typically small companies. And all they do is try to get small companies with products that don't work across the finish line. They have a different business model. And by
SPEAKER_00the way, their audience is also the companies themselves, which pay for their conferences, which supply panelists. They have dual role,
SPEAKER_01journalists and panelists for the conference run by the company. Also, who else would subscribe to those outlets other
SPEAKER_00than that? Who else would read it? So, did you ever try, and I assume that with the stats or the biospace, with those places, it's just hopeless to try to have a conversation with them because they're too financially incented to listen. What about What about the New York Times, though, or the Washington Post? Were you ever able to say to them, look, where did you guys get into the business of carrying water for Pfizer?
SPEAKER_00Because as a former New York Times reporter, this is something that I don't understand.
SPEAKER_01It's hopeless, Alex. I mean, Alex, look what we're talking about. We're talking about people who, till this day, they'll read a study that says the shingles vaccine decreased Alzheimer's disease, heart attacks, all-cause mortality by 25%. Ergo, yet another reason why Bobby Kennedy is wrong. They don't ask themselves, not one minute do they think maybe the people who didn't get the shot were sicker than those who got it. They would sooner think the shingle shot can regrow hair from male pattern baldness than they will concede that the shingle shot may not do that.
SPEAKER_01They can't read. This is not meant to be offensive. I know it's going to sound that way, but you're a rare journalist that you have somehow learned to read studies. I don't think that's common.
SPEAKER_00I almost have more sympathy, or I do have more sympathy for doctors. Because if you're a doctor, you have to treat patients. Certainly, if you're in one tiny subspecialty, you can know everything there is to know. But if you're internal medicine or even a cardiologist who doesn't have some subspecialty, you have... You have a lot to know and a lot of people to treat and an office to run and a holiday to St. Bart's to book or whatever.
SPEAKER_00You got a lot to do. But seriously, I do have sympathy for the people who are busy treating patients and can't necessarily read the appendix to the NEJM study. But I expect reporters to do that. And they don't do it.
SPEAKER_01Or at a minimum, just talk to one expert who has a different point of view. Literally on any of these issues, just talk to one expert with a slightly different point of view. Why can't they do that? I don't understand.
SPEAKER_00And that's a failure of my profession, not yours.
SPEAKER_01But you say, like, is it possible that, you know, even if you think, can Bobby Kennedy be right for the wrong reason? Like, they won't even allow him that, to be right for the wrong reason. They won't even give him that. You know, can somebody be right for the wrong reason? No, they are really so set against, you know, when Trump one came around and he kept saying fake news and they're out to get me, you know, I never believed him. Now I kind of see his point that we've become so polarized and the people who work there are so much on the other team, rooting for the other team, that when they say, listen, Alex, if you've had COVID, Right.
SPEAKER_01It's, it's,
SPEAKER_00Yes. So, were you able to, I mean, so you put out this paper, there's strong blowback, and then in February, I believe, I'm sure it was February, actually, you, and I think I said this to you at some point, I thought you made a tactical mistake. You... You said no to the mRNA flu vaccine submission from Moderna on the basis that the vaccine had been compared to the wrong vaccine,
SPEAKER_00that it hadn't been compared to the more powerful traditional flu vaccine. And so you weren't going to accept their submission. And to me, that was a mistake because it was too easy for the company and the journalists who support the company and its friends at the White House to say, you know, he won't even look at the data. We spent close to a billion dollars on this study, you know, study or, you know, developing this vaccine. And this guy thinks he's too good even to look at the data after we've run the study.
SPEAKER_00Yeah. If you had to do that again, would you do it differently? At that point, did you already sort of see, you know what, I'm not going to be able to survive here much longer? What was going through your head, you know, as 2026 sort of rolled on and your position became more and more difficult? Yeah.
SPEAKER_01Okay, well, let's come to this. But I'll just start by saying one thing. I don't believe you should take a job like this and think, what can I do to keep myself in this job? If you start to think that way, you'll end up being like all of the people who've held jobs who have done literally nothing to benefit this country. And they go to Washington to do good and they stay to do well. And there are so many of them Most of the former HHS secretary, you can go through the list of all these people who literally, you can't even name one thing they ever did in their life.
SPEAKER_01They literally sat in the office looking at their golf clubs on the side and then went to play golf. So I'm not going to do that. I'm going to do what I think is right. Now let's talk about this particular issue. We issued a refuse to file. The statutory requirement for filing, for accepting a filing, is that the company has conducted an adequate and well-controlled study. This company was seeking an approval of a novel mRNA flu shot.
SPEAKER_00This company is Moderna.
SPEAKER_01Moderna. Yeah. And they're seeking approval for flu shot in an age group in a single indication above the age of 50, which includes an indication where the control arm of their study has not been the standard of care for arguably a decade.
SPEAKER_00Meaning for people over 65, they're supposed to get this theoretically and I guess actually more potent flu vaccine.
SPEAKER_01Yeah, and for a decade, we have known that that adjuvanted or high-dose flu shot has better outcomes for that elderly group of people for a decade. If your dad has MDS, should we enroll him in a study of a new novel drug for MDS? Versus bloodletting from leeches. I take it to an extreme. The point is that it's so bad for patients to participate in a study where the control arm is not the best available standard of care. They're taking on risk for getting a product that's done worse than what we were already doing.
SPEAKER_01I find it, we allow it so often in the United States, and I find it so ethically problematic. If it were your own father or mother, you'd say, oh, you know what, we'll skip that. You're on the randomized control arm. We're going to skip and just go to CVS and get the good stuff for my dad. But you all knock yourselves out and be randomized. So anyway, so we refused to file because they had applied for something with an evidentiary package that, in my opinion, did not include an adequate and well-controlled study. They later resubmitted, having truncated their approval into two different age groups,
SPEAKER_01an age group where it was more arguable what their control arm was, 50 to 64, and an age group that wasn't. And they actually ultimately didn't get the approval that they wanted in the beginning. They have an accelerated approval for 65 and up and not a regular approval, so there's a confirmatory study. But to your point, you said money. You said that it cost a billion dollars to run this study. My understanding is it's something like that. But my understanding is that there was an external third-party group that paid that tab and not the company itself. And interesting, people should start to ask who paid for that and why.
SPEAKER_01Yeah. Yeah.
SPEAKER_00Okay, so you felt that scientifically this was the correct decision, but it did not hold up. You faced immediate, there was an immediate storm of criticism of you for, by my count, at least a fourth time. The Sarepta stuff, the mRNA stuff, this, and I guess the Huntingtons. Maybe that wasn't as much you, was it?
SPEAKER_00Well, anyway, at least three times you were on or near the front page of the Wall Street Journal and the New York Times getting lambasted. And so, do you feel... Not
SPEAKER_01inaccurate, yeah.
SPEAKER_00Do you feel like... You didn't want to compromise. You're not a guy who compromises. Would we as a country be better off With you still at the FDA making some compromises, let's say, about this particular issue, for example, where allowing Moderna to file this and then either accepting or rejecting it on the data rather than saying, look, I think this was a mistake.
SPEAKER_00I think someone at the FDA should have told you this six years or three years ago or whenever you began the study. But you know what? You You diligently did do this and we did allow it and I'm not going to pull the rug out from under you now, even though I don't think this was the best trial design. Would the world be better off? Would the United States be better off? Would patients be better off having you fallen on your sword a little bit on that and still at the FDA now?
SPEAKER_01You know, it's an interesting question, but I'll throw it to you a little bit, Alex, because you early on in the pandemic said cloth masking was useless. And you said a toddler shouldn't wear a face diaper. OK, now, arguably, those positions, which are 100 percent correct, by the way, they always were correct. They still are correct. But at the time you said it, those positions really pushed you to the fringe. So could you have retained that and stayed in and tried to publish more op-eds the New York Times? And I think the answer you're going to give me is the answer that I'm going to give you, which is that,
SPEAKER_01boy, we really need to be able to, as a society, to call out the obvious things. A cloth face diaper, as you called it, didn't help us. It was just an empty panacea, which tokens that humans have used for millennia through pandemics continue to be used. You know, the modern day plague costume. Similarly... Similarly, in this case, I think that, you know, there are people who want the mRNA flu shot because they believe that someday in
SPEAKER_01the future, it'll allow us to come up with a pandemic flu, blah, blah, blah, blah, blah. But there are very few people who look at that study and look at the adverse event profile in that study and actually think to themselves, boy, Let me roll up my sleeve and get this. And I think that more people should do the right thing, Alex. You did the right thing back in 2020. When I read your writing, even the few times you and I have disagreed, we talk about it by email, but I never once think... You're pulling your punches. And I think I'm cut from the same cloth as you, Alex.
SPEAKER_00No, I mean, we definitely are cut from the same cloth. I don't think I would have lasted at the FDA any longer than you did. What I'm still asking is a harder question, which is, would we be better off if you were still there right now? It's too small a question.
SPEAKER_01If you pulled back a little bit, would
SPEAKER_00you be able to do some good?
SPEAKER_01It's too small a question because like, you know, like what have we really created in the agency? I mean, I think maybe it's worth stepping back and just thinking about what the agency does. The agency does, they do two things. We regulate research, we regulate products on the market. The research The research we regulate is sometimes we block research that shouldn't be done because it's harmful. Sometimes we block research that should have been done. We're wrong to block it. And then sometimes we facilitate research that should have been blocked. And sometimes we facilitate research that should have been facilitated. It's a huge job at the FDA to regulate all the INDs and all the sort
SPEAKER_01of investigational applications across the space in America. It's a huge and onerous and bureaucratic job. And as a general philosophy, we make both mistakes, but I think we probably do sometimes put up too many roadblocks to doing research. That's my honest view. Then the second thing we do is we regulate marketing and making huge amounts of money from products. And because we put the FDA logo on it, you can charge $477,000 a year. If we didn't have the FDA logo on it, you probably wouldn't be able to charge that. You'd have to charge a much lower amount. And there, I think you could talk about two errors, like rejecting things that are meritorious.
SPEAKER_01I don't see examples of us making that error. I see a lot of the other way, which is we accept things that are mediocre or probably harmful if they don't work because we're just under tremendous political pressure. So we have to ask ourselves as a country, do we really want $5 trillion of our capital stuck in a system where you have a group of unelected bureaucrats in a couple of counties making multi-billion dollar decisions and, you know, getting a lot wrong? And I'll see you next time.
SPEAKER_01So could Vinay Prasad, a Vinay Prasad that, you know, didn't do a refuse to file when it was warranted and didn't talk about COVID-19 deaths when it was warranted, could he solve that? I don't think so. I just think that Vinay Prasad is just too small a character in a broader story.
SPEAKER_00So, I mean, do you think that the FDA, would we be better off with no FDA? Would we be better off with the situation where it was sort of You know, everybody, every company would have to decide what to market and there'd be insurance companies that would ask for data or that there's no that there'd be no central federal clearinghouse. I can't imagine that that would be a better system, but you seem to be on the verge of saying that might be a better system.
SPEAKER_01I think that you haven't done justice to the, I can't answer the question. I think it's an unanswerable question and we're data people, there's no data. But I think you haven't done due diligence on imagining the question correctly. Okay. So I think most people imagine the question of, are we better off with the FDA as it is? Or that pre-1962 world or 1904 world where it was snake oil people selling you their tonics from their wagon cart. And of course, we'd all agree, okay, we're better off now than this. But in a world where we didn't have the federal government step in for this,
SPEAKER_01well, maybe let me pause and say one thing. Why did the federal government step in? It stepped in for two reasons, from Upton Sinclair's work on food safety in 1906 with the original Food and Drug Administration, and then it stepped in again after thalidomide in the 1960s. And thalidomide gave us safety and efficacy, which is ironic because thalidomide It might actually lower morning sickness, but it had a safety problem. It didn't have an efficacy. You know, efficacy wasn't the top of mind with thalidomide. So it was two seminal, large events in American history that gave us the FDA as it is. If we didn't have those events or if those events were a little bit less dramatic,
SPEAKER_01Um, what would have emerged in the place of the FDA? I don't think it would be a free for all like it was in 1902. I think what would have emerged is the same thing that emerges in all these other parts of hospital medicine, which is, um, different standards and accreditations, different third parties, um, You know, and is that better or worse? I don't know. But it would largely kind of satisfy the same needs as to try to weed out the snake oils from the real treatments. And everyone is trying to do this at tremendous cost.
SPEAKER_01So, I mean, I don't know the answer to the question, but a world without the FDA, I think there would be third party like lead certifications for drugs and things like that.
SPEAKER_00And you think that that could actually be... Put to the test yes or no to the FDA as the system we now have with all its flaws or let's knock it down and see what springs up. Which would you choose?
SPEAKER_01To be honest, if you put a gun to my head, I would favor much more aggressive reforms for all these domains. Should the federal government have to pay for any cancer medicine approved by the FDA? No. Should the FDA be telling a person who wants to pay out of pocket that they can't do some things? No. But should the FDA be giving the seal of approval to things that don't work? No. And we haven't talked about safety, but the COVID-19 vaccines do illustrate that.
SPEAKER_01We talk about myocarditis, I think that's a well-documented safety signal. I don't agree with everything people think is attributable to the vaccine, but is it plausible that some things that we don't consider attributable actually are attributable? Yeah, and we don't do a good job. We have no mechanism in society or medicine to do those things. I think healthcare in medicine... Oh, let me give you one more analogy, the AI regulation. I think we disagree a little bit about AI regulation. It's not that I agree with them that this is a huge risk and something bad may happen,
SPEAKER_01but I'm not sure if government is the agency that can fix this by creating an independent regulator and hiring people and all these kinds of things and creating a new AI regulation. I'm skeptical of that claim.
SPEAKER_00Right. And I think you're right to be skeptical. I don't know what to do about AI either, but I mean, it's fine. We've been on this for almost an hour. I really want to do this again on a weekend because I feel like we should have 10 times the number of people that we have right now. And, you know, it's sometimes hard for people to watch during the workday. But, you know, we haven't talked about the GLPs. We haven't talked about plague. We haven't talked about, you know...
SPEAKER_00What you think of how much you got to see RFK Jr. up close and what you think of him. There's a bunch of stuff.
SPEAKER_01I like him. I like him as a person.
SPEAKER_00He's funny. Let me ask that and then open it to one or two questions and then I will let you go. But you have to promise me we're going to do this again soon.
SPEAKER_01Yeah, I think those are all good topics. I'm also on Substack, Vinay Prasad's Observations and Thoughts. I subscribe to Alex.
SPEAKER_00I just, you know, I hadn't subscribed to you because a friend of mine sent me everything that you wrote and just forwarded the emails, but now I've subscribed.
SPEAKER_01Okay, thanks. You want to take questions from the audience or what's your last question about RFK? Tell me, you know, a
SPEAKER_00How often you saw RFK and what you think of him because you said you liked him, but was he able to do what he wanted to do from your point of view? And then we'll take a question or two.
SPEAKER_01I think what I like about him is I think he's persuadable and the places that I disagreed with him a little bit, I think he was very open to that feedback. What I like about him is that Listen, anyone who comes along in American politics that's able to energize a portion of the American electorate and push for important reforms, those are rare people. And whether you, whatever people may say, you know, he said one thing here or there. He said a lot of things here or there that I would say I completely don't agree with. And I've written so many things debunking those things he said. But show me a politician in American medicine that's serious about reforming healthcare.
SPEAKER_01I haven't seen it in my life, you know, or even willing to like go against the people making all this money. And I think we have to take what we get in this space. I don't know who the next one will be. And then the second part of your question, has he been able to accomplish what I think he had hoped? I think, sadly, probably the glass will be more empty than full. I think he's accomplished some things, but boy, the political pushback. Anytime you threaten the way large amounts of cash move through the system, you're going to get an immune reaction like you've never experienced.
SPEAKER_01And I think he is in the midst of that.
SPEAKER_00And that's really curtailed his ability to do some things. Yes, yes.
SPEAKER_01And one irony is, boy, isn't it ironic that a lot of the things that the left of center, progressive, liberal media would have wanted to happen in drug regulation when it was brought by the people they don't like, they'd rather just shoot themselves in the foot and not get what they would have wanted.
SPEAKER_00It is amazing. It really is amazing how, and I think you're right, you said it earlier, it's personal. They don't like him.
SPEAKER_01They don't like him.
SPEAKER_00And listen, the shirtless push-ups or whatever, there's some ridiculous stuff.
SPEAKER_01Yeah, the Wi-Fi, the shirtless push-ups, the cell phone. Yeah, there's some ridiculous stuff. The bear in Central Park.
SPEAKER_00But overall, you view him as a positive force.
SPEAKER_01I just feel like what motivates me as a voter is like it needs to be disrupted. It needs disruption in healthcare. Like do we need another Javier Becerra? Tell me one thing Javier Becerra ever did as HHS secretary. Tell me one thing. And you know, like, and I know Scott Gottlieb loves to do his victory laps. Tell me one useful thing Scott Gottlieb ever did. Before or after. If you can tell me, I'll keep my inbox open.
SPEAKER_00Well, you know, he made himself some good money advice.
SPEAKER_01Oh, yes. He stayed to do well. And same for Javier. Yeah.
SPEAKER_00But all right. So we'll take one or two questions. And yes, I really want to do this again. Actually, somebody on the chat said, next time, I'm not going to paywall it because hopefully we'll do it on a weekend. I want 2,000 people on this the next day. But so, yes. But you're going to release the video.
SPEAKER_01A lot of people watch this video.
SPEAKER_00Yes. For those of you who are out there listening, throw us a question or two. You got five minutes.
SPEAKER_01We'll see if anybody has anything good.
SPEAKER_00Somebody says you haven't mentioned industry conflicts of interest at FDA. I think you did do that, actually. But, you know, is there anything to say about Pidufa or...
SPEAKER_01Oh, God. I mean, like, I think Padufa, like, one is the revolving door. I mean, people who work there and they work in pharma, it's like, it's just like one to the other. Yeah. I think we should also be realistic, which is that if you go there and the skill set you develop, it's particularly well suited for people seeking favorable regulatory action. So, you know, I don't truly beat them up for that too much. At the same time, you know, boy, you got to look at it as an American voter and think to yourself,
SPEAKER_01you know, is the person working there really being? Are they committed to the best interest of the American people or are they aspiring to be the chief medical officer of Pfizer? Who, by the way, was a former CEDAR director, right? That's a former CEDAR director. So this kind of, that's one thing, quid pro quo, a politician gets a donation and that politician leans on FDA for favorable action. That's a problem. The fact that the fees come from PDUFA, You know, people say, well, what's the problem? It's like, you know, the New York Times charges subscriptions, but subscribers don't decide the content. Yeah, but in this case, different centers can build empires on PDUFA fees.
SPEAKER_01Cedars is like $2 billion in PDUFA fees. And CBER would be a lot more powerful if we approved more things and got more PDUFA money. Yeah. So it's like in government, if you're a mid-level government bureaucrat, if that is your childhood dream, it wasn't mine, but if it is yours, then you'd want to be at an agency that can siphon massive amounts of financial revenue. And PDUFA is a great way to siphon it that's not dependent on Congress or spending appropriations, et cetera. Yeah. You know, every sector of regulation inherently has some capture by the industry regulated for
SPEAKER_01the simple reason, like why does the rabbit run faster than the fox? The rabbit runs for his life and the fox runs for a meal. And so like the average person in America doesn't have that much interest in FDA, rightfully so. If I wasn't in healthcare, I wouldn't care either because it's only cents on our dollar. But for the person on the other end of the regulatory decision, it's their whole, it's a hundred X career return on investment, you know? Right. Right.
SPEAKER_00Right. We have two people saying, why didn't you stay and fight? I think you answered that. You felt it was more important to stand on principle, right? I mean, is that the one sentence response to that?
SPEAKER_01I see. Better to die on your feet than live on your knees. There you go.
SPEAKER_00Someone asked for your opinion on Tamiflu.
SPEAKER_01Scamiflu? Scamiflu or Tamiflu? I couldn't hear you. I was thinking Paxlovid or Scamlovid. I would say that, you know, Tamiflu, the preponderance of the randomized control trial evidence as analyzed by Jefferson and colleagues in the British Medical Center. Journal, I think 2014 is the year, showed almost no improvement in hospitalizations or ICU stays or death, small improvements in how long you have the flu at the price of increased nausea in the first 24 hours. Similarly,
SPEAKER_01we have a recent Tamiflu study that looked at hospitalized patients where it increased mortality that was halted, I believe, in Europe. And Paxlovid is the same thing. If you never had had COVID and you had a high risk of bad outcomes and you had never had a shot, Paxlovid looked favorable back in the diggity. But if you've had had COVID or you had had a shot or you had had both, getting a Paxlovid for the second or third time, like our former President Biden, had no evidence to support it and now has a negative randomized control trial panoramic in addition to Epic SR.
SPEAKER_01So I think that these kinds of antivirals have done very poorly.
SPEAKER_00Well, we have, there's like three or four specific questions. I'm going to, since it's 359, I'm going to fold into one big question, which is, are you optimistic or pessimistic about both drug development and even more broadly, the American healthcare system going forward? In 10 years, are we going to be talking about the same, assuming the robots don't eat us all, which I, let's just hope they don't.
SPEAKER_00Are we going to be talking about the same problems except it'll be 10 trillion instead of 5 trillion? Is there anything that's going to change the trajectory the system is on right now, in your opinion?
SPEAKER_01I think it's exactly as you described. Ten years from now, we'll be talking about the same problems, but it will be $10 trillion. It'll be a larger percentage of GDP. What are we, 18%, 19% GDP, 20%? We'll be at 25%, 26%, 27% of GDP. You know, Alex, I guess... Rome fell when half the days in the Roman city were holidays. And America, when half of GDP is healthcare, only then will we say, okay, we got to do something about this GDP healthcare business. We are an animal that's inherently responsible.
SPEAKER_01We're really bent on treating ourselves and scanning ourselves and living forever, even if what we're doing doesn't accomplish that goal. And as long as you have a system where understanding medical evidence is challenging, which you do, it requires skepticism, it requires bravery, it requires being able to speak your mind like you able to say these cloth masks or diapers at a time where there's professional pressures not to do that. I'm sure there are personal pressures not to do that. I think it takes a thick skin to do that. Like you're a unique individual.
SPEAKER_01And it takes a certain level of bravery to even question that what people are telling you. And I don't think we have enough of it. And I don't think we will mount enough of it. I think the money flows in one way.
SPEAKER_00And so it'll just get bigger and bigger. And so, okay, you know, individuals like me or you aside, there's no structural reform you can see. There's nothing where Whether it's the CMS or the employers or there's nobody who's going to say, hey, we really need to change fundamentally the way we're doing this. No, no, I don't.
SPEAKER_01I think I feel like I don't know what has given you that optimism. Where does that come from? Was it Braille? Is it Braille that gave you the optimism? Do you see this? Like, you know, talk about moving the goalposts on. Well, first of all, Congress has passed a law that the that these blood tests are going to get covered when they're FDA approved. Right. And then they've known the sensitivity and specificity for years on these tests. And then they run a randomized study powered for a low endpoint phase three, four, stage three, four disease. They fail to hit even the modest endpoint they concocted.
SPEAKER_01And then they still. They're still going to get it from the older data. There's no bar low enough that can't be sanded down further. And the reason is all of the money is moving in that direction. The best you can hope to do in the system is that there are still real discoveries along the way that really do help patients. And I think the best we can hope to do is contribute to those real discoveries along the way. Yeah. But reforming the system,
SPEAKER_01you need a president with both houses of Congress who this is like their sole issue and they don't care about the midterms or lobbyists or any dollars.
SPEAKER_00That will never happen, I guess. You did answer the question. All right, listen. Promise me we'll do this again. We'll do it on a weekend when more people can see it. And no paywall, because I do, I think, I think it's fascinating. And we didn't, yeah, we didn't talk, we didn't talk about anything that's happened in the last few weeks with the GLPs or any of that stuff. So part two will be, this was the FDA. This was, this was for the fans. Next time we're going to talk about like big healthcare stuff that's happening right now.
SPEAKER_01Sounds lovely. And in the meantime, I'll continue to appreciate your writing, Alex.
SPEAKER_00And vice versa. Good to talk to you, Vinay.
Live episode from Youtube This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.drvinayprasad.com/subscribe
Elizabeth Holmes/ AI researchers start smoking/ Moderna vax by Plenary Session This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit...
Pope has cancer; Phase 1 trials for AI; Can AI hack cancer trials__1 by Plenary Session This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit...